Compare · ANTX vs AZN
ANTX vs AZN
Side-by-side comparison of AN2 Therapeutics Inc. (ANTX) and AstraZeneca PLC (AZN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANTX and AZN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $261.92B, about 1553.9x ANTX ($168.6M).
- Over the past year, ANTX is up 330.3% and AZN is down 10.3% - ANTX leads by 340.6 points.
- AZN has been more active in the news (15 items in the past 4 weeks vs 4 for ANTX).
- AZN has more recent analyst coverage (25 ratings vs 13 for ANTX).
- Company
- AN2 Therapeutics Inc.
- AstraZeneca PLC
- Price
- $4.69+0.00%
- $168.85-0.24%
- Market cap
- $168.6M
- $261.92B
- 1M return
- -2.29%
- -5.56%
- 1Y return
- +330.28%
- -10.32%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- 2026
- News (4w)
- 4
- 15
- Recent ratings
- 13
- 25
AN2 Therapeutics Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest ANTX
- Director Aziz Kabeer was granted 2,852 shares, increasing direct ownership by 5% to 59,106 units (SEC Form 4)
- Director Marks Gilbert Lynn was granted 2,789 shares, increasing direct ownership by 4% to 81,873 units (SEC Form 4)
- Director Martin Patricia A. was granted 766 shares, increasing direct ownership by 4% to 18,863 units (SEC Form 4)
- Officer Eizen Joshua M sold $24,803 worth of shares (5,945 units at $4.17), decreasing direct ownership by 3% to 206,554 units (SEC Form 4) to satisfy tax liability
- AN2 Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
- Principal Accounting Officer Williams Sarah Joanne sold $1,174 worth of shares (265 units at $4.43), decreasing direct ownership by 0.40% to 66,583 units (SEC Form 4) to satisfy withholding obligation
- AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by AN2 Therapeutics Inc.
- AN2 Therapeutics upgraded by Leerink Partners with a new price target
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC